Literature DB >> 18559408

Alternative methods to evaluate trial level surrogacy.

Josè Cortiñas Abrahantes1, Ziv Shkedy, Geert Molenberghs.   

Abstract

BACKGROUND: The evaluation and validation of surrogate endpoints have been extensively studied in the last decade. Prentice [1] and Freedman, Graubard and Schatzkin [2] laid the foundations for the evaluation of surrogate endpoints in randomized clinical trials. Later, Buyse et al. [5] proposed a meta-analytic methodology, producing different methods for different settings, which was further studied by Alonso and Molenberghs [9], in their unifying approach based on information theory.
PURPOSE: In this article, we focus our attention on the trial-level surrogacy and propose alternative procedures to evaluate such surrogacy measure, which do not pre-specify the type of association. A promising correction based on cross-validation is investigated. As well as the construction of confidence intervals for this measure.
METHODS: In order to avoid making assumption about the type of relationship between the treatment effects and its distribution, a collection of alternative methods, based on regression trees, bagging, random forests, and support vector machines, combined with bootstrap-based confidence interval and, should one wish, in conjunction with a cross-validation based correction, will be proposed and applied. We apply the various strategies to data from three clinical studies: in opthalmology, in advanced colorectal cancer, and in schizophrenia.
RESULTS: The results obtained for the three case studies are compared; they indicate that using random forest or bagging models produces larger estimated values for the surrogacy measure, which are in general stabler and the confidence interval narrower than linear regression and support vector regression. For the advanced colorectal cancer studies, we even found the trial-level surrogacy is considerably different from what has been reported. LIMITATIONS: In general the alternative methods are more computationally demanding, and specially the calculation of the confidence intervals, require more computational time that the delta-method counterpart.
CONCLUSIONS: First, more flexible modeling techniques can be used, allowing for other type of association. Second, when no cross-validation-based correction is applied, overly optimistic trial-level surrogacy estimates will be found, thus cross-validation is highly recommendable. Third, the use of the delta method to calculate confidence intervals is not recommendable since it makes assumptions valid only in very large samples. It may also produce range-violating limits. We therefore recommend alternatives: bootstrap methods in general. Also, the information-theoretic approach produces comparable results with the bagging and random forest approaches, when cross-validation correction is applied. It is also important to observe that, even for the case in which the linear model might be a good option too, bagging methods perform well too, and their confidence intervals were more narrow.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18559408     DOI: 10.1177/1740774508091677

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  4 in total

1.  Center-Within-Trial Versus Trial-Level Evaluation of Surrogate Endpoints.

Authors:  Lindsay A Renfro; Qian Shi; Yuan Xue; Junlong Li; Hongwei Shang; Daniel J Sargent
Journal:  Comput Stat Data Anal       Date:  2014-10-01       Impact factor: 1.681

2.  A Comparison of Logistic Regression, Logic Regression, Classification Tree, and Random Forests to Identify Effective Gene-Gene and Gene-Environmental Interactions.

Authors:  Wonsuk Yoo; Brian A Ference; Michele L Cote; Ann Schwartz
Journal:  Int J Appl Sci Technol       Date:  2012-08

Review 3.  Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials.

Authors:  Qian Shi; Daniel J Sargent
Journal:  Int J Clin Oncol       Date:  2009-04-24       Impact factor: 3.402

4.  Determining Cutoff Point of Ensemble Trees Based on Sample Size in Predicting Clinical Dose with DNA Microarray Data.

Authors:  Selen Yılmaz Isıkhan; Erdem Karabulut; Celal Reha Alpar
Journal:  Comput Math Methods Med       Date:  2016-12-20       Impact factor: 2.238

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.